Combination Chemotherapy with IL-2 and IFN-α for Melanoma
Author Information
Author(s): J Atzpodien, K Neuber, D Kamanabrou, M Fluck, E B Bröcker, C Neumann, T M Rünger, G Schuler, P von den Driesch, I Müller, E Paul, T Patzelt, M Reitz
Primary Institution: European Institute for Tumor Immunology and Prevention (EUTIP)
Hypothesis
Does combination chemoimmunotherapy improve outcomes compared to chemotherapy alone in metastatic melanoma?
Conclusion
The study found no significant benefit of adding IL-2 and IFN-α to chemotherapy for patients with metastatic melanoma.
Supporting Evidence
- The overall response rate for chemoimmunotherapy was 34.3%, while it was 29.9% for chemotherapy alone.
- Median overall survival was 12 months for chemoimmunotherapy and 13 months for chemotherapy.
- Patients with liver metastases had significantly shorter survival compared to those without.
Takeaway
Doctors tested a new treatment for skin cancer but found it didn't work better than the usual medicine.
Methodology
Patients were randomized to receive either chemotherapy alone or chemotherapy followed by IL-2 and IFN-α.
Potential Biases
Potential biases in patient selection and treatment administration may affect results.
Limitations
The study did not establish a standard treatment or significant survival benefit for the combination therapy.
Participant Demographics
41 females and 83 males, aged 18 to 75, with histologically confirmed metastatic melanoma.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI, 9, 49
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website